New scan could spare patients unnecessary bone biopsies

NCT ID NCT05934994

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a detailed bone scan (SPECT-CT) can accurately tell if a single suspicious bone lesion is benign or malignant. Researchers will compare the scan results to biopsy findings in 68 adults. If the scan works well, it could help some people avoid the risks of an unnecessary biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Bone scan (SPECT-CT)
What this could lead to: If successful, this scan could help doctors safely rule out cancer in suspicious bone spots without needing a biopsy.
What could go wrong: This is a small, early-stage study (68 people) testing a new way to use an existing scan. It may not prove accurate enough to replace biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 68 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Person, having received complete information on the organization of the research and having signed the informed consent and: * Age ≥ 18 years old. * Having read and understood the information document. * Affiliated to a social security scheme. * Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy +/- excision is planned. Exclusion Criteria: * Pregnant woman or woman of childbearing age and without contraceptive means or nursing mother. * Unstable medical condition and/or inability to remain still during recordings. * Known allergy to one of the components of the radiopharmaceutical technetium-99m-Technescan HDP (product required to perform the bone scan). * Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code. * Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1, L. 3213-1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone lesion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone lesion

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New scan could spare patients unnecessary bone biopsies

What the study statuses mean